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Despite a heightened appreciation of the many defining molecular aberrations in Ewing
sarcoma, the cooperative genetic environment and permissive cell of origin essential
for EWS/ETS-mediated oncogenesis remain elusive. Consequently, inducible animal and
in vitro models of Ewing sarcoma from a native cellular context are unable to fully
recapitulate malignant transformation. Despite these shortcomings, human, and murine
mesenchymal stem cells (MSCs) are the closest working in vitro systems available.
MSCs are tolerant of ectopic EWS/FLI expression, which is accompanied by a molecular
signature most similar to Ewing sarcoma. Whether MSCs are the elusive cell of origin
or simply a tolerant platform of the EWS/FLI transcriptome, these cells have become an
excellent molecular tool to investigate and manipulate oncogenesis in Ewing sarcoma. Our
understanding of the biological complexity and heterogeneity of human MSCs (hMSCs)
has increased substantially over time and as such, appreciation and utilization of these
salient complexities may greatly enhance the efficient use of these cells as surrogate
models for Ewing sarcoma tumorigenesis.
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INTRODUCTION
Ewing sarcoma is an aggressive translocation-derived malignancy
primarily affecting adolescents and young adults. Balanced chro-
mosomal rearrangements fusing the transcriptional activating
domain of the EWSR1 (Ewing sarcoma breakpoint region 1) gene
in frame to the carboxy-terminal DNA binding domain of one
of five ETS (E-26) family transcription factors are observed in
virtually all tumors (reviewed in Sankar and Lessnick, 2011).
EWS/FLI fusions aremost common, present in 85–90% of tumors
(Delattre et al., 1994; Janknecht, 2005; Sankar and Lessnick,
2011). The EWS/FLI chimera functions as an aberrant oncogenic
transcription factor, dysregulating numerous down-stream gene
targets (May et al., 1993a,b). Genome-wide sequencing efforts
have reproducibly defined a comprehensive EWS/FLI transcrip-
tional signature, characterized by both up- and down-regulated
gene targets (Prieur et al., 2004; Kinsey et al., 2006; Smith et al.,
2006; Gangwal et al., 2008; Patel et al., 2012). Gene silencing
using RNAi-mediated technologies suggests oncogenesis in Ewing
sarcoma is dependent on EWS/FLI expression (Prieur et al.,
2004; Kinsey et al., 2006; Smith et al., 2006). Otherwise, these
tumors are relatively genomically stable and as such, EWS/FLI
and related EWS/ETS fusions are felt to be the master regula-
tors of oncogenesis in Ewing sarcoma. This relationship pro-
vides a unique opportunity to further understand the precise
molecular events responsible for Ewing sarcoma susceptibility
and pathogenesis. Detailed in this review, in the absence of an
inducible in vitro or in vivo model of transformation in Ewing
sarcoma, multipotent mesenchymal stromal cells [a.k.a. mes-
enchymal stem cells (MSCs)] have emerged as not only the most
likely candidate cell of origin, but provide a workable cellular plat-
form to which EWS/FLI-mediated transformation can be more
thoroughly characterized and understood. MSCs are an enigmatic
population of cells; our understanding of the biological complex-
ity of these cells continues to evolve, as do techniques to harvest
these cells from a variety of anatomical sources. As such, a com-
prehensive understanding of the salient features of MSC isolation,
characterization, and biological attributes is warranted.
HISTOGENESIS IN EWING SARCOMA
Unfortunately, despite the inferred hierarchical simplicity of
EWS/FLI-mediated gene dysregulation in Ewing sarcoma, in vitro
and animal models have been unable to fully recapitulate the pro-
cess of oncogenic transformation under conditions of induced
EWS/FLI expression in normal cells and tissues. These challenges,
in part stem from an inability to define the precise histogenesis of
Ewing sarcoma. Histologically, Ewing sarcoma is an undifferenti-
ated small round blue cell tumor and in contrast to many other
cancer models, a direct lineage-specific differentiation of Ewing
sarcoma has not been proven. For example, ectopic expression
of EWS/FLI in a variety of non-malignant human and animal
cell lines is either toxic (Lessnick et al., 2002), induces a gene
signature discordant with that observed in patient-derived cell
lines (Braunreiter et al., 2006) or is simply incapable of mediat-
ing the entire phenotypic spectrum of oncogenic transformation
(Lessnick et al., 2002; Riggi et al., 2008). Although beyond the
scope of this review, the two most likely “cell of origin” candidates
in Ewing sarcoma are neural crest stem cells (NCSC) and mes-
enchymal progenitor cells/mesenchymal stem cells (MPC/MSC).
Supporting a neuroectodermal lineage is that ectopic EWS/FLI
expression is tolerated in NCSC (von Levetzow et al., 2011)
and gene expression profiles and cell surface antigens in Ewing
sarcoma are commonly expressed in neural tissues and NCSCs
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(Lipinski et al., 1987; Staege et al., 2004; von Levetzow et al.,
2011). Conversely, given the predominant skeletal location of pri-
mary tumors, a presumed mesenchymal progenitor origin seems
likely and indeed, a growing body of literature supports a mes-
enchymal origin of Ewing sarcoma. Ectopic EWS/FLI expression
is tolerated in both human and mouse-derive mesenchymal stem
cells (Riggi et al., 2005, 2008; Miyagawa et al., 2008) and the sub-
sequent EWS/FLI-mediated gene signature closely parallels that
observed in patient-derived cell lines and primary tumor sam-
ples (Miyagawa et al., 2008; Riggi et al., 2008). Alternatively,
RNAi-mediated repression of EWS/FLI in patient-derived cells
lines results in a reprogrammed genetic profile similar to that
of mesenchymal stem cells (Tirode et al., 2007; Potikyan et al.,
2008; Kauer et al., 2009). Interestingly, there is mounting evi-
dence advocating that human MSCs (hMSCs) are derived from
neuroepithelium via a neural crest intermediate (Takashima et al.,
2007; Mendez-Ferrer et al., 2010), suggesting the true cell of ori-
gin in Ewing sarcoma may in fact reside along a continuum of the
NCSC-MSC progenitor lineage.
Importantly, a global skepticism of these aforementioned cell
progenitor models of Ewing sarcoma is that ectopic EWS/FLI
expression in either mesenchymal or neural crest progenitors
has been unable to consistently recapitulate the full phenotypic
spectrum of oncogenic transformation. This maturing evidence
suggests a mere permissive cell environment may be insufficient
for transformation, prompting speculation that in addition to
EWS/ETS gene fusions, other mutations, epigenetic phenomena,
or cell cycle modifications are cooperatively necessary in Ewing
sarcoma.
MODELING OF EWING SARCOMA USING MESENCHYMAL
STEM CELLS
Numerous cell types have been manipulated in hope to model the
induction of EWS/ETS-mediated oncogenesis, including human
rhabdomyosarcoma cells, human neuroblastoma cells, mouse
and human MPC, NIH3T3 fibroblasts, and human telomerase
reverse transcriptase (hTERT)-immortalized human fibroblasts
(Lessnick et al., 2002; Rorie et al., 2004; Hu-Lieskovan et al., 2005;
Riggi et al., 2005, 2008). Given the highly undifferentiated state of
Ewing sarcoma cells, the predominant skeletal location of these
tumors, and the expansive anatomic abundance of MSCs, it is
of no surprise reports characterizing ectopic EWS/ETS expres-
sion in both animal and hMSCs emerged in parallel with effective
and reproducible techniques to isolate and characterize these cell
types.
MURINE MSCMODELS
Ectopic expression of EWS/FLI in murine BM-MSCs was first
described by Torchia et al. (2003) and unlike previous reports in
human fibroblasts (Lessnick et al., 2002) stable EWS/FLI expres-
sion did not result in growth arrest or senescence. Furthermore, it
was demonstrated that osteogenic and adipogenic differentiation
was also impeded by EWS/FLI expression. Notably, the cultured
BM-MSC came from INK4A/ARF deficient mice and no pheno-
typic assays of transformation were assessed such as proliferation
assays, anchorage independent growth or xenograft tumor for-
mation. However, these initial results importantly demonstrated
tolerable EWS/FLI expression in murine MSCs and the capa-
bility of EWS/FLI to repress lineage-specific differentiation. In
a similar series of experiments using a murine myoblast cell
line (C2C12), which is capable of osteogenic, myogenic, and
adipogenic differentiation, Eliazer and colleagues (2003) demon-
strated a comparable tolerance of ectopic EWS/FLI expression
and impaired terminal differentiation into muscle and bone.
Similar to the Torchia et al. model, in vitro and in vivo assays
testing transformation potential of these cells was not assessed.
A more comprehensive look at ectopic EWS/FLI expression in
murine MSCs was later reported by Castillero-Trejo et al. (2005)
and Riggi et al. (2005). Interestingly, both EWS/FLI-expressing
MSCmodels were capable of forming tumors in immunodeficient
mice. In the Riggi et al. study, subcutaneously injected EWS/FLI-
expressing MSCs developed detectable tumors within 6 weeks.
Histologically, these tumors appeared as sheets of small round
blue cells and stained positive for common Ewing sarcoma cell
surface markers, CD99, and NSE (Kovar et al., 1990; Ambros
et al., 1991; Amann et al., 1999). Furthermore, these transformed
MSCs maintained wild type p16INK4A/p19ARF and a functional
p53. Dysregulation of IGF-1 and TGFβRII gene expression, two
commonly up- and down-regulated targets in Ewing sarcoma,
respectively, were also observed (Prieur et al., 2004; Smith et al.,
2006). Importantly, these effects of EWS/FLI expression were
not observed in murine embryonic stem cells. However, CD99
expression in this murine model has been since questioned
as the immunoreactive extracellular domain of murine CD99
is highly divergent from humans (Kovar and Bernard, 2006).
Using a slightly different approach, Castillero-Trejo et al. (2005)
obtained stable EWS/FLI expression in MSCs procured from
young mice (3–4 weeks). Using intravenous, intra-peritoneal
or subcutaneous routes of administration, EWS/FLI-expressing
MSCs rapidly developed into tumors in syngeneic mice. It was
also noted that the efficiency of tumor induction was positively
correlated with an increasing number of cell passages. Early pas-
sage and late passaged cells demonstrated a constitutively high
expression of p53, while p21 expression (an up-regulated tar-
get of p53) gradually decreased with increasing cell passage.
Acquired mutations in p53 were observed in some but not all
of these late passage cells, however, using a Cre-transduced loxP-
EWS/FLI construct, it was shown that MSC transformation is
still highly EWS/FLI-dependent in early and late passage cells.
Unfortunately, a comprehensive Ewing sarcoma gene expression
profile was not documented in either study, questioning whether
these transformed MSCs were definitively Ewing sarcoma.
A major concern using mouse-derived cells to model Ewing
sarcoma is that Ewing sarcoma appears to be exclusively a
human disease; spontaneous Ewing sarcomas have not been
reported in other animal species. Additionally, the gene expres-
sion profiles of experimental “Ewing sarcoma-like” cells derived
from murine NIH3T3 cells differ greatly from that observed
in humans (Braunreiter et al., 2006). For example, two consis-
tently up-regulated gene targets necessary for transformation in
human-derived Ewing sarcoma cell lines, NR0B1, and NKX2.2
are not dysregulated in murine-derived cells (Owen and Lessnick,
2006; Gangwal et al., 2008). It is known that EWS/FLI and
related EWS/ETS fusions up-regulate numerous target genes via a
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promoter-based GGAAmicrosatellite response element (Gangwal
et al., 2008, 2010; Guillon et al., 2009). These GGAA microsatel-
lites are essential for EWS/ETS DNA binding and gene activation,
yet these elements are absent in the murine orthologs of key up-
regulated targets necessary for oncogenic transformation, such as
NR0B1, CAV1, and GSTM4 (Tirado et al., 2006; Gangwal et al.,
2008; Luo et al., 2009). Another concern is that murine-derived
MSC expanded in culture have also been shown to sponta-
neously transform in as few as three passages, attributable to
spontaneous chromosomal translocations and genomic instabil-
ity (Miura et al., 2006; Zhou et al., 2006). Human cells are
generally regarded as more challenging to transform than their
mouse counterparts, which are easily transformed and produce
seemingly more aggressive tumors (Akagi, 2004).
HUMANMSC MODELS
Given these aforementioned limitations of murine MSCs and the
propensity of Ewing sarcoma to develop exclusively in humans,
inducible models utilizing human-derived MSCs intuitively pro-
vide a better in vitro model of histogenesis and EWS/FLI-
mediated transcriptional regulation. Despite numerous ethical,
cost, and access-related challenges associated with human MSC
isolation and manipulation, numerous reports utilizing these cell
types have emerged. Riggi and colleagues (2008), using similar
techniques to their earlier work with murine MSCs, obtained
stable expression of EWS/FLI in human bone derived-MSCs
(hMSCEWS/FLI). Cell populations were isolated from a more
“aged” adult population undergoing hip and knee replacement
surgeries. Ectopic EWS/FLI expression in these cells resulted in
typical morphological changes (cellular rounding and increased
nuclear to cytoplasmic ratio) and profound up-regulation of
CD99. It was noted that control hMSCs had a low basal expres-
sion of CD99. These morphological changes were accompanied
by a modified gene expression profile highly concordant with
public data sets from established Ewing sarcoma tumors and cell
lines. When tested against a publicly available database of bone
and soft tissue sarcomas (Baird et al., 2005), the experimental
hMSCEWS/FLI gene set most closely matched Ewing sarcoma, with
an observed overlap of 40 (p < 0.00001). Classic EWS/FLI tar-
get genes such as NKX2.2, NR0B1, IGF1, COL11A1, MMP1, and
EZH2 were also up-regulated in this data set. EWS/FLI expression
also induced numerous genes encoding neuroectodermal markers
or neuronal differentiation pathways such asNYP1R,GRP, MSX1,
ERG2, NKX2.2, NGFR, and SOX2. Interestingly, the life span and
proliferation characteristics of the hMSCEWS/FLI population were
unchanged from control hMSC populations, which had a life
expectancy of only 3 months. Additionally, in sharp contrast to
previous studies in murine-derived MSCs, the hMSCEWS/FLI cells
maintained tri-lineage differentiation capabilities into bone, fat
and cartilage. Despite the compelling gene expression character-
istics hMSCEWS/FLI, tumors failed to develop when injected into
the subcapsular renal component of immunocompromised mice.
Using a slightly different approach, Miyagawa and colleagues
(2008), developed a tetracycline-inducible model of EWS/FLI
expression in a human MSC line, UET13. Uniquely, this cell line
is immortalized using human telomerase (hTERT) and E7 viral
transgenes, while maintaining tri-lineage differentiation abilities.
UET13EWS/FLI cells demonstrated morphological changes and
CD99 up-regulation comparable to Riggi et al. (2008), however,
they observed an apoptosis-independent growth inhibition of
induced cells. Ectopic EWS/FLI expression also resulted in cell
surface immunophenotypes and gene expression profiles consis-
tent with Ewing sarcoma, although no in vitro or in vivomeasures
of transformation were assessed.
After the same group recently reported CD133+ cancer stem
cell (CSC) subpopulations in dissociated primary Ewing sar-
coma tumors (Suva et al., 2009), Riggi et al. (2010) tested
the hypothesis that similar CD133+ CSC populations could be
identified using their previously described hMSCEWS/FLI model.
Using a slightly different approach, they manipulated two dis-
tinct hMSC populations: hMSCs isolated from an older adult
population and a younger pediatric population ranging in age
from 6 to 14 years old. They observed similar mRNA and pro-
tein levels of EWS/FLI, cell surface immunophenotypes and
tri-linage differentiation capabilities between adult and pedi-
atric hMSCsEWS/FLI but noted a markedly increased proliferation
rate in the pediatric-derived cells. Gene expression profiles were
also dissimilar between the two groups: pediatric hMSCsEWS/FLI
induced greater expression of common EWS/FLI targets,NKX2.2,
IGF1, SOX2, NPY1R, GRP, and EZH2 and exhibited a greater gene
overlap with the Baird et al. dataset of bone and soft tissue sarco-
mas (Baird et al., 2005) when compared to adult hMSCsEWS/FLI.
This overlapping Ewing sarcoma molecular signature was even
more pronounced when pediatric hMSCsEWS/FLI were expanded
in a serum-free media. Serum-starved growth conditions have
been shown to facilitate genetic reprograming of differentiated
human andmurine cells into induced pluripotent stem cells (iPS)
(reviewed in Jaenisch and Young, 2008). Using these conditions,
pediatric hMSCsEWS/FLI strongly up-regulated numerous genes
associated embryonic stem cells such as OCT4, SOX2, NANOG,
and C-MYC. OCT4 and NANOG were not expressed in adult
hMSCsEWS/FLI and expression of these stem cell-associated targets
increased 20-fold in serum starved pediatric hMSCsEWS/FLI.
As a previously established cell surface marker of Ewing sar-
coma CSCs, CD133 expression was scarce in adult hMSCsEWS/FLI
but increased 15-fold and 250-fold in pediatric hMSCsEWS/FLI
expanded in normal and serum-free conditions, respectively.
These data interestingly demonstrate phenotypic differences in
adult and pediatric hMSCs populations expressing EWS/FLI, sug-
gestive that cells from pediatric sources have a greater proliferative
ability, have a EWS/FLI-mediated transcriptome most similar to
Ewing sarcoma tumors and cells lines and furthermore, are more
likely to show evidence of genetic reprogramming toward a more
pluripotent, stem cell phenotype. Unfortunately, similar to their
preceding work, in vitro and in vivo transformation capabilities of
these more “Ewing sarcoma-like” pediatric hMSCsEWS/FLI were
not assessed and/or reported.
Data frommurine and humanMSC models of Ewing sarcoma
have demonstrated that these progenitor cells afford a permis-
sive or compatible cellular environment, tolerant of EWS/FLI
expression with minimal toxicity. Changes in cell morphology,
CD99 up-regulation, neuroectodermal characteristics, repressed
differentiation status and global gene expression profiles are all
strikingly similar to profiles of Ewing sarcoma cell lines and
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primary tumors. Despite these common features, ectopic expres-
sion in hMSCs does not fully recapitulate oncogenic transfor-
mation. Robust xenograft tumor development in murine-derived
MSCs expressing EWS/FLI challenge this assertion, however,
evidence obtained by modeling Ewing sarcoma, an exclusively
human malignancy in human cells justifiably takes scientific
precedence over non-human model systems at this point in time.
Synthesizing this information it is possible that MSCs merely
provide a cellular environment tolerant of the EWS/FLI onco-
protein and the aforementioned genetic and phenotypic alter-
ations observed in MSCsEWS/FLI are simply a manifestation of
the EWS/FLI transcriptional signature and the true cell of ori-
gin remains elusive. Conversely, MSCs may indeed be the most
probable cell of origin, however other crucial genetic alterations
either up- or down-stream of the principal defining EWS/ETS
translocation event, cooperatively necessary for malignant trans-
formation have yet to be identified. These challenges are further
appreciated when considering the various attempts to develop
a transgenic mouse model of Ewing sarcoma: constitutively
expressed EWS/FLI is embryonic lethal (Torchia et al., 2007),
where inducible, tissue-specific expression of EWS/FLI in MPC
resulted in limb bud developmental abnormalities (Lin et al.,
2008). Although somewhat encouraging, using this same trans-
genic model in a p53 deficient background resulted in poorly
differentiated sarcomas (Lin et al., 2008).
Irrespective of our evolving understanding of molecular
paradigm of transformation in Ewing sarcoma, MSC have proven
to be a reliable, readily obtainable, scientific tool and will have
numerous applications moving forward. hMSCs can be obtained
from a variety of adult, pediatric and post-natal tissues and cul-
tured using various techniques. It is becoming increasingly appar-
ent that these subtle differences greatly influence down-stream
applications. Consequently, understanding these complexities is
important, as these progenitor cells are becoming an increasingly
useful platform to answer the principal questions proposed above.
MESENCHYMAL STEM CELL BASICS
DISCOVERY
The osteogenic properties of bone marrow elements have been
understood dating back to the 19th century, although it was
only 50 years ago when Friedenstein and colleagues identified a
sub-population of non-hematopoietic bone marrow-derived cells
capable of osteogenic differentiation (Owen and Friedenstein,
1988). Initially coined “osteogenic stem cells,” these cells (or
highly related populations) have since been shown capable of
multi-lineage differentiation into fat, muscle, bone, cartilage, ten-
don, fibrous tissue, and were subsequently re-assigned the title of
“mesenchymal stem cells” in the late 90’s (Dennis and Caplan,
1996; Pittenger et al., 1999). Since then, these pluripotent cells
have adopted numerous titles such as “multi-potent mesenchy-
mal progenitor cells,” “mesenchymal stromal cells,” “skeletal stem
cells” and so forth. Existing in an uncommitted state, under
the appropriate signaling environment these cells posses repro-
ducible lineage-specific regenerative abilities and more recently,
have been shown to modulate elements of the immune sys-
tem and are being intensively developed for tissue regeneration
purposes (reviewed in Chamberlain et al., 2007). Consequently,
scientific inquisition into the finer biological attributes of these
cells has gained considerable traction over the past two decades.
MSC ISOLATION
The warehouse of mesenchymal stem cells was traditionally
viewed as the stromal component of bone marrow, largely in part
to the origins of cell discovery in this location. Subsequently, a
vast array of anatomic sites have been recognized as a reliable
deposit of these cells and includes compact bone, adipose tissue,
peripheral blood, and placental tissues such as the umbilical
cord, umbilical cord blood (UCB), the placenta, and amniotic
fluid (Wagner et al., 2005; Riggi et al., 2008; Hass et al., 2011).
hMSCs are commonly isolated from the mononuclear cell layer
of the aforementioned tissues after cell dissociation and density
gradient centrifugation. Various pre- and post-centrifugation
techniques have been described to enrich the mononuclear
cell layer with likely MSC populations including hypotonic
red blood cell lysis buffers, negative selection antibody beads
(removing hematopoietic stem cells) and cell sorting using
a FACS or MACS-type systems. Culture conditions for the
mononuclear cell extract are extremely variable (Wagner et al.,
2005; Miyagawa et al., 2008; Riggi et al., 2008; Secco et al., 2008;
Malgieri et al., 2010; Peters et al., 2010), but commonly include
a minimal growth medium such as Minimal Essential Medium
(MEMα) or Dulbecco’s Modified Eagle’s Medium (DMEM),
supplemented with 10% fetal bovine serum, antibiotics, and
antifungals. In a study by Sotiropoulou et al. (2006), use of
MEMα media supplemented with L-glutamine (MEMα-LG) or
glutamax (MEMα-GL) afforded the most optimal MSC growth
conditions. Various recombinant growth factor such as fibroblast
growth factor basic (bFBF), epidermal growth factor (EGF)
and platelet derived growth factor-BB (PDGF-BB) are potent
mitogens, prolonging the proliferative life span of MSCs and are
important medium supplements for rapid cellular expansion,
while maintaining a non-committed state (Lennon et al., 1995;
Tamama et al., 2006; Ng et al., 2008). However, there is concern
that these growth factor supplements may direct subtle and often
unwanted lineage commitment. For example, the most common
growth factor additive to MSC media, bFGF has been shown to
favor differentiation toward osteogenic lineages and suppresses
neurogenic potential (Martin et al., 1997; Sotiropoulou et al.,
2006). Mononuclear cells are then expanded on tissue culture
plastic and after 3–4 days of culture, non-adherent cells, most of
which are of hematopoietic origin are discarded. MSCs comprise
the adherent cell population in addition to some hematopoietic
progenitor cells, which are progressively washed away over time.
Growth characteristics of early cultured MSC are characterized
by an initially lag phase lasting 3–4 days, followed by more
rapid proliferation phase with population doubling times highly
dependent on the anatomic site/fluid of procurement and the
age of the subject (D’Ippolito et al., 1999; Stenderup et al., 2003;
Baksh et al., 2007; Hass et al., 2011).
MSC CHARACTERIZATIONAND PHENOTYPIC HETEROGENEITY
Phenotypically, MSCs express a variety of cell surface markers,
although none are entirely MSC-specific. It is agreed upon that
MSC lack the expression of hematopoietic markers such as CD45,
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CD34, CD14, or CD11 and the endothelial marker CD31, but
generally express, CD44, CD71, CD73, CD90, CD105, Stro-1,
and adhesion molecules such as vascular cell adhesion molecule
(VCAM-1), intercellular adhesion molecule (ICAM-1), activated
leukocyte cell adhesion molecule (ALCAM) and CD29. The con-
stellation of these expressed surface markers does vary depending
on the tissue source, isolation and culture techniques and popu-
lation doublings (comprehensively reviewed in Hass et al., 2011;
Chamberlain et al., 2007; Malgieri et al., 2010). Regardless, a
precise panel of cell surface markers specific to MSCs, let alone
tissue-specific MSCs, has not been established.
Consequently, perhaps the most important defining attribute
of presumed mesenchymal stem cell populations is functional.
As presumed precursors of mesenchymal tissue, tri-lineage dif-
ferentiation potential of these cells into fat, bone, and cartilage
is a vital identifying characteristic of MSCs. These multi-potent
characteristics are routinely assessed under in vitro conditions:
osteogenic differentiation is achieved by exposing cell mono-
layers to ascorbic acid, β-glycerophosphate and dexamethasone.
Differentiation is identified using alizarin red and von Kossa
stains. Chondrogenic differentiation is promoted by centrifug-
ing cells into pellets and exposing these masses to transform-
ing growth factor beta (TGF-β). Strong toluidine blue staining
and expression of collagen type II are indicative of chondroid
differentiation. Lastly, adipogenic differentiation is achieved by
exposing cell monolayers to insulin, dexamethasone, isobutyl-
methly-xanthine, and indomethacin. Lipid rich vacuoles within
cells are easily identified by oil red O staining (Mackay et al., 1998;
Pittenger et al., 1999; Lee et al., 2004; Dominici et al., 2006; Secco
et al., 2008).
It is now generally accepted that cells expressing and lacking a
consistent core signature of MSC cell surface markers, in addi-
tion to inducible tri-lineage differentiation into bone, cartilage
and fat adequately define a mesenchymal stem cell population. In
keeping with this, the International Society for Cellular Therapy
(ISCT) has established a minimal set of guidelines used to
characterize and define “multipotent mesenchymal stromal cells,”
also abbreviated MSC. Using these guidelines, presumptive MSC
populations must possess the following phenotypic features:
adherence to tissue culture plastic, expression of surface markers
CD73/CD90/CD105, absent expression of CD34/CD45/CD14 or
CD11b/CD79α or CD19/HLA-DR, and tri-lineage differentiation
into osteoblasts, chondroblasts, and adipocytes (Dominici et al.,
2006). Table 1 summarizes the ISCT guidelines and described
phenotypic differences between human MSC from various tissue
sources.
SALIENT FEATURES OF HUMANMSCs—IMPLICATIONS FOR
EWING SARCOMAMODELING
hMSC PROLIFERATION AND DIFFERENTIATION CAPABILITIES
In the most basic terminology, “stem cells” are commonly
regarded as undifferentiated precursor cells capable to prolif-
eration, self-renewal and differentiation into multiple lineage-
specific progeny (Blau et al., 2001). Based on in vitro behavior,
MSCs possess many of these attributes however, MSCs do not
possess an unlimited proliferative potential and the differentia-
tion potential of MSCs lessens with increasing cell passages. For
example, BM-MSCs, show phenotypic and molecular evidence of
senescence after 10–30 population doublings, which is also associ-
ated with decreased osteogenic and chondrogenic differentiation
capabilities (Colter et al., 2000; Chen et al., 2012). Low-density
seeding of hMSCs has been shown to increase cell proliferation
rates and life expectancy, although to a limited extent (Colter
et al., 2000). Interestingly, adipogenic differentiation appears to
be less affected by cell passages (Chen et al., 2012). In the Riggi
et al. model of hMSCEWS/FLI, both control and experimental
MSCs stopped proliferating at 3 months (Riggi et al.). The het-
erogeneous cellular constitution of most density gradient-derived
mononuclear cell isolates often necessitates numerous cell pas-
sages to remove contaminating adherent hematopoietic cells,
Table 1 | hMSC sources and biological characteristics.
Positive cell surface
antigens
Negative cell surface
antigens
Tri-lineage
potential
Isolation
frequency
Self renewal potential
ISCT guidelines for
“Multipotent
mesenchymal
stromal cells” (MSC)
>95% cells: CD73
(SH3/SH4), CD90
(Thy-1), CD105 (SH2)
<2% cells: CD34,
CD45, CD14 or CD11b,
CD79 or CD19,
HLA-DR
Osteogenic
Adipogenic
Chondrogenic
n/a Unspecified
Bone marrow-derived
MSC (BM-MSC)
CD13, CD44, CD73,
CD90, CD105, CD166,
STRO-1
CD14, CD31, CD34,
CD45, HLA-DR
Osteogenic
Adipogenic
Chondrogenic
± Neurogenic
1/105–106 MNCs
100% isolation
efficiency
Susceptible to contact inhibition
Doubling time = 40–60 h
Senescence 10–30 PD
Adipose
tissue-derived MSC
(AT-MSC)
CD9, CD13, CD29,
CD44, CD54, CD73,
CD90, CD105, CD106,
CD146, CD166, STRO-1
CD11b, CD14, CD19,
CD31, CD34, CD45,
CD79, CD133, CD144
Osteogenic
Adipogenic
Chondrogenic
± Neurogenic
1/104–105 MNCs
100% isolation
efficiency
Susceptible to contacy inhibition
Doubling time = 45 h
Senescence 10–30 PD
Umbilical cord blood
derived MSC
(UC-MSC)
CD29, CD44, CD73,
CD90, CD105
CD19, CD31, CD33,
CD34, CD45, CD90,
CD117, CD133, CD135,
HLA-DR
Osteogenic
Chondrogenic
Neurogenic
Adipogenic
1/107–108 MNCs
30–70% isolation
efficiency
Resistant to contact inhibition
Doubling time = 24 h
Senescence 30–80 PD
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potentially diminishing the “stem cell capabilities” of harvested
MSCs.
To circumvent these issues, immortalizing cells with retrovi-
ral hTERT, SV40 T-antigen and E7 transgenes can substantially
prolong the proliferative life span of hMSCs without loss of tri-
lineage potential (Terai et al., 2005; Wolbank et al., 2009; Li
et al., 2010). There is, however, discrepancy in the literature as
to whether telomerase immortalized hMSCs can transform over
time. In one study, after 256 population doublings, the hTERT-
transduced MSC line, hMSC-TERT20 was shown to sponta-
neously transform in vitro and in xenograft transplants (Serakinci
et al., 2004), whereas other studies have failed to demonstrate any
transformation abilities in these immortalized cell types (Terai
et al., 2005; Wolbank et al., 2009). As described earlier, ectopic
expression of EWS/FLI in an immortalized hMSC line (UET-13)
has been investigated, although in vitro and in vivo transforma-
tion abilities of these cells were not assessed and/or reported
(Miyagawa et al., 2008). Certainly for the purposes of in vitro
modeling of Ewing sarcoma, immortalization of hMSCs can be
easily achieved, is unlikely to affect transformation under 100 PDs
and may greatly increase the window of opportunity to select a
homogenous population of MSCs without losing the stem cell
phenotype.
AGE-RELATED BIOLOGICAL ATTRIBUTES OF MSCs
In regards to the biological potential of animal and hMSCs, there
is no doubt that agematters. It has been shown that the number of
hMSCs isolated from bonemarrow is greatest at birth and steadily
decreases with increasing age (Caplan, 2009). Furthermore, pro-
liferation rates, life expectancy, differentiation capabilities and
contact inhibition are markedly reduced in human and animal
MSCs harvested from older subjects (D’Ippolito et al., 1999;
Stenderup et al., 2003; Hass et al., 2011; Chen et al., 2012).
Liposomal transfection rates of hMSCs are also negatively affected
by an aging source (Baksh et al., 2007). Given that Ewing sar-
coma is primarily a pediatric disease, Riggi et al. (2010) compared
ectopic EWS/FLI expression in pediatric and adult-derivedMSCs.
Pediatric MSCs had a greater proliferation rate, shared more
molecular similarities to Ewing sarcoma and had greater expres-
sion of NCSC and Ewing sarcoma CSCmarkers compared to their
adult counterparts. Explanations for these findings remain unre-
solved, but it is clear there are intrinsic differences between adult
and pediatric/neonatal hMSCs, which may provide a more acces-
sible molecular environment for EWS/FLI-mediated transcrip-
tional regulation. It should be noted that pediatric hMSCsEWS/FLI
have not been shown to transform in vitro or in vivo suggest-
ing the age-related molecular biology of these cells is unlikely
the missing genetic alteration required for EWS/FLI-mediated
transformation.
TISSUE-SPECIFIC ATTRIBUTES OF hMSCs
Since their discovery, MSCs have been successfully isolated from
a diverse spectrum of human tissues and fluids. Presently, the
most common sources of MSCs are bone marrow, compact bone,
adipose tissue, and placental tissues such as umbilical cord and
UCB (Riggi et al., 2005; Kern et al., 2006; Malgieri et al., 2010;
Hass et al., 2011). The frequency of MSCs in each of these
tissues and the success at which these cells can be cultivated
varies considerably (Table 1). Adipose tissue is the most abundant
source of MSCs, followed closely by bone marrow, whereas MSCs
are relative scarce in UCB and peripheral blood (Pittenger et al.,
1999; Kern et al., 2006; Rebelatto et al., 2008). These num-
bers likely contribute to the high success of MSC isolation from
bone marrow and adipose tissue and the inconsistent numbers
reported for UCB (Wagner et al., 2005; Kern et al., 2006; Hass
et al., 2011). Functionally, it is generally accepted that irrespective
of the tissue source, MSCs exhibit relatively consistent tri-lineage
differentiation potential.
Culturing and expanding placenta-derived MSCs has gained
increasing traction for numerous reasons: unlike BM-MSCs and
AT-MSCs, procurement of placental-derivedMSCs is not painful,
invasive or associated with procedural complications. Placental
tissues are regarded as medical waste and are in abundant sup-
ply, therefore a plentiful source of MSCs. Placentas are a neonatal
tissue and therefore provide a MSC population with more desir-
able “young” growth characteristics and life expectancy (Kern
et al., 2006; Lu et al., 2006; Baksh et al., 2007). Moreover,
MSCs from UCB are more primitive and exhibit greater pluripo-
tent plasticity than MSCs isolated from adult tissues (Sarugaser
et al., 2005; Lu et al., 2006). Ewing sarcoma models have not
been attempted in UCB-MSCs, although the favorable biological
attributes of these MSCs may provide a better age-related bio-
logical platform for future studies. There are some drawbacks of
UCB-MSCs, namely UCB is also a source of adherent endothelial
progenitors cells, which may contaminate adherent MSC pop-
ulations (Broxmeyer et al., 2006). Although, CD31 is a reliable
endothelial marker and cell-sorting techniques could be used to
circumvent this problem. Additionally, roughly 15–20% of UCB
samples are contaminated with low numbers of maternal blood
cells (0.04–5.0%) (Hall et al., 1995; Tsang et al., 2002). However,
given the paucity of MSCs in peripheral blood, the mesenchy-
mal progenitor burden of this maternal contamination would be
exceeding low.
FUTURE DIRECTIONS AND CONCLUSIONS
Attempts to delineate the precise cell of origin in Ewing sar-
coma have demonstrated that MSCs can indeed be used as
a functional molecular vehicle to investigate the consequences
of EWS/FLI expression in a native cellular context. Modeling
Ewing sarcoma using MSCs will be an important strategy mov-
ing forward; profiling genetic differences between incompletely
transformed MSCs and Ewing sarcoma tumors and cell lines
may help identify the elusive genetic perturbations required for
transformation. EWS/FLI-expressing hMSCs may also facilitate a
greater understanding of how EWS/ETS chimeras interact with
DNA elements and cooperative proteins in a more native cellular
environment. However, the intricacies hMSC isolation, identifi-
cation and experimental manipulation have greatly evolved over-
time. Consequently, effective use of these multipotent stem cells
requires a more detailed understanding of the salient age-, tissue-
and culture-associated aspects of MSC biology. Utilizing pedi-
atric or neonatal tissue sources in combination with transgenic
methods of immortalization may ultimately improve accessibility
and passage-related hurdles, while potentially providing a more
representative, pluripotent cell population implicated in Ewing
sarcoma.
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